

## Special Issue

# Targeted Therapies for Epilepsy

### Message from the Guest Editors

When epilepsy is already established, new antiseizure medications (ASMs) may also be suitable. Indeed, despite the availability of various ASMs, one-third of patients suffering from epilepsy are considered “drug-resistant” and cannot achieve satisfactory seizure control. In this case, a major obstacle in developing new targeted therapies for epilepsy, and especially drug-resistant epilepsy, is that the mechanisms of drug resistance are still scarcely understood. In addition to this, most patients with chronic intractable epilepsy are resistant to different mechanistically distinct anti-seizure medications.

Another important goal for a new targeted therapy for epilepsy should be to avoid the adverse effects of ASMs, which normally result in drug discontinuation.

For these reasons, new chemical compounds, and alternative potential therapies such as neurostimulation, dietary treatments, gene therapy, and cell transplantation, can be proposed to control epilepsy.

---

### Guest Editors

Prof. Dr. Giuseppe Biagini

Dr. Anna-Maria Costa

Dr. Chiara Lucchi

---

### Deadline for manuscript submissions

closed (20 February 2025)



## Pharmaceuticals

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.8  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/si/175059](https://mdpi.com/si/175059)

*Pharmaceuticals*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)

[mdpi.com/journal/  
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





# Pharmaceuticals

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.8  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/journal/  
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



## About the Journal

### Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

---

### Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)